Proactive Investors - Run By Investors For Investors

Silence Therapeutics adds new siRNA asset to pre-clinical pipeline for potential treatment of cardiovascular disease

The firm, a leader in the discovery, development and delivery of novel RNA therapeutics, said the proprietary product candidate, SLN360, silences apolipoprotein, a component of lipoprotein(a) (LP(a)
Therapeutics testing
Silence Therapeutics said that an Investigational New Drug/Clinical Trials Application for SLN360 is anticipated to be filed in the second half of 2020

Silence Therapeutics PLC (LON:SLN) has added a new siRNA (short interfering RNA) asset to its pre-clinical pipeline for the potential treatment of cardiovascular disease.

The firm, a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, said the proprietary product candidate, SLN360, silences apolipoprotein, a component of lipoprotein(a) (LP(a).

WATCH: Silence Therapeutics CEO looks ahead to clinical trial next year and prospects for RNAi

David Horn Solomon, of Silence Therapeutics‘ chief executive officer, commented: "We are excited to add SLN360, our new LP(a) targeting siRNA medicine, to our pipeline of wholly-owned assets aimed at addressing areas of significant unmet need.”

He added: “High LP(a) levels in humans increase the probability of significant cardiovascular disease and lowering these levels is associated with reducing cardiovascular risks and disease. Our data suggest that SLN360 significantly reduces serum LP(a) in non-human primates for up to two months and ultimately will use patient convenient sub-cutaneous dosing."

“We are poised to advance SLN360 towards the clinic as a new medicine for patients with significant cardiovascular risk," Solomon concluded.

Silence Therapeutics said that an Investigational New Drug/Clinical Trials Application for SLN360 is anticipated to be filed in the second half of 2020.

In a note to clients, analysts at ‘house’ broker Peel Hunt said: “We see this as a positive step for the company as new management focus much more on the building the pipeline – adding this to the Silence’s asset for beta-thalassemia and myelodysplastic syndrome (SLN124).”

They added: “We continue to review our valuation methodology following resolution of the recent litigation but this asset will add NPV to the portfolio/platform on a risk-adjusted basis.”

In mid-morning trading, Silence Therapeutics’ shares were 0.7% higher at 55.20p.

 -- Adds analyst comment, share price --

View full SLN profile View Profile

Silence Therapeutics PLC Timeline

Related Articles

pills
January 15 2019
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
Alliance
April 05 2019
Chief executive Peter Butterfield said the company has started 2019 well-positioned for growth after a strong performance in 2018.
lab worker
May 20 2019
Here we take a closer look at Scancell, which is at the vanguard of immuno-oncology

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use